Bristol's Opdivo Enjoys IO First-Mover Advantage In Small Cell Lung Cancer
In addition to Opdivo, three other PD-1/L1 inhibitors are in late-stage development for a high-unmet need disease, including Roche's Tecentriq, which will be filed as soon as possible.
You may also be interested in...
In top-line final Phase III results from KEYNOTE-604, Keytruda improves PFS but not OS when combined with chemotherapy for the first-line treatment of small-cell lung cancer.
Opdivo failed to meet an overall survival endpoint in a Phase III confirmatory study in small-cell lung cancer. But several analysts think Bristol will keep the SCLC labeling obtained in August due to lack of treatment options for these patients.
Roche's combination of Tecentriq with chemotherapy is ahead of rivals in first-line SCLC and has been filed with the US FDA.